

**APPENDIX**

<b>Supplementary Table 1. Non-significant predictors of treatment intensification with apalutamide, abiraterone, enzalutamide, or chemotherapy among de novo metastatic castration-sensitive prostate cancer patients in Alberta, Canada</b>					
<b>Variable</b>	<b>Overall (n=1576)</b>	<b>ADT alone (n=1031)</b>	<b>Treatment intensification (n=545)</b>	<b>Crude OR (95% CI)</b>	<b>Adjusted OR (95% CI)</b>
Residence (%) <sup>1</sup>					
Rural	470 (30.2)	327 (31.9)	143 (27.0)	Ref	Ref
Urban	1084 (69.8)	697 (68.1)	387 (73.0)	<b>1.28 (1.01– 1.63)</b>	1.10 (0.78– 1.64)
Neighborhood household income (%) <sup>1</sup>					
<35 000	316 (20.3)	209 (20.4)	107 (20.2)	Ref	Ref
35 000–<45 000	509 (32.8)	342 (33.4)	167 (31.5)	0.94 (0.40– 0.65)	1.06 (0.70– 1.59)
45 000–<55 000	373 (24.0)	245 (23.9)	128 (24.2)	1.00 (0.72– 1.38)	0.97 (0.61– 1.53)
55 000+	356 (22.9)	228 (22.3)	128 (24.2)	1.05 (0.75– 1.45)	1.01 (0.63– 1.62)
Neighborhood high school education (%) <sup>1</sup>					
<0.70	277 (17.8)	189 (18.5)	88 (16.6)	Ref	Ref
0.70–<0.80	424 (27.3)	298 (29.1)	126 (23.8)	0.87 (0.62– 1.23)	0.88 (0.58– 1.33)
0.80–<0.90	587 (37.8)	364 (35.5)	223 (42.1)	1.30 (0.96– 1.79)	1.24 (0.79– 1.95)
0.90+	266 (17.1)	173 (16.9)	93 (17.5)	1.05 (0.72– 1.52)	1.11 (0.66– 1.89)

*Gotto et al. Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer*

**APPENDIX**

ER visits + hospitalizations (%)					
0	652 (41.4)	411 (39.9)	241 (44.2)	Ref	Ref
1	248 (15.7)	156 (15.1)	92 (16.9)	1.03 (0.75–1.40)	0.88 (0.58–1.33)
2	233 (14.8)	155 (15.0)	78 (14.3)	0.83 (0.60–1.15)	0.91 (0.56–1.47)
3	146 (9.3)	99 (9.6)	47 (8.6)	0.84 (0.56–1.24)	1.08 (0.62–1.86)
4+	297 (18.8)	210 (20.4)	87 (16.0)	<b>0.67 (0.49–0.91)</b>	0.75 (0.45–1.23)
Practitioner claims count (%)					
<10	307 (19.5)	182 (17.7)	125 (22.9)	Ref	Ref
10–<20	429 (27.2)	264 (25.6)	165 (30.3)	0.90 (0.66–1.22)	0.93 (0.62–1.41)
20–<30	294 (18.7)	194 (18.8)	100 (18.3)	<b>0.68 (0.48–0.96)</b>	0.90 (0.56–1.44)
30–<40	214 (13.6)	134 (13.0)	80 (14.7)	0.84 (0.58–1.21)	1.33 (0.77–2.23)
40+	332 (21.1)	257 (24.9)	75 (13.8)	<b>0.40 (0.28–0.57)</b>	0.83 (0.47–1.45)

<sup>1</sup>22 patients were missing postal code (7 for ADT and 15 for treatment intensification).

ADT: androgen deprivation therapy; CI: confidence interval; ER: emergency room; OR: odds ratio.